Table 1.

Baseline clinical and demographic characteristics in the infant treatment groups

	P2-VP8-P[8] vaccine 10 μg (n=12)	P2-VP8-P[8] vaccine 30 μg (n=50)	P2-VP8-P[8] vaccine 60 μg (n=50)	Placebo (n=50)
	Age, days	46·2 (1·7)	46·5 (2·7)	47·1 (3·1)	46·2 (2·5)
Male sex	5 (42%)	23 (46%)	25 (50%)	24 (48%)
Black ethnicity	12 (100%)	49 (98%)*	50 (100%)	50 (100%)
Length, cm	54·5 (2·5)	54·7 (2·6)	55·7 (1·5)	55·3 (2·3)
Weight, kg	5·1 (0·7)	4·8 (0·6)	4·9 (0·5)	4·8 (0·6)

Data are n (%) or mean (SD).

^*One infant (2%) had mixed ethnicity.